A Phase 2b, Open-Label, Long-Term Extension Study to Evaluate the Safety and Pharmacodynamics of KRN23 in Adult Subjects With X-Linked Hypophosphatemia (XLH)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 07 Feb 2018
At a glance
- Drugs Burosumab (Primary)
- Indications X-linked dominant hypophosphataemic rickets
- Focus Adverse reactions
- Sponsors Ultragenyx Pharmaceutical
- 31 Jan 2018 Planned End Date changed from 16 Aug 2018 to 30 Sep 2019.
- 31 Jan 2018 Planned primary completion date changed from 16 Aug 2018 to 24 Nov 2018.
- 31 Jan 2018 Status changed from recruiting to active, no longer recruiting.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History